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LiverNon-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of hepatic histopathological changes ranging
fromnon-inﬂammatory intracellular fat deposition to non-alcoholic steatohepatitis (NASH),whichmay progress
into hepatic ﬁbrosis, cirrhosis, or hepatocellular carcinoma. NAFLD hallmark is the excessive hepatic accumula-
tion of neutral lipids that result from an imbalance between lipid availability and lipid removal. Recent data sug-
gest that disturbed hepatic cholesterol homeostasis and liver free cholesterol (FC) accumulation are relevant to
the pathogenesis ofNAFLD/NASH. Hepatic FC accumulation inNAFLD results from alterations in intracellular cho-
lesterol transport and from unbalanced cellular cholesterol homeostasis characterized by activation of cholester-
ol biosynthetic pathways, increased cholesterol de-esteriﬁcation and attenuation of cholesterol export and bile
acid synthesis pathways. FC accumulation leads to liver injury through the activation of intracellular signaling
pathways in Kupffer cells (KCs), Stellate cells (HSCs) and hepatocytes. The activation of KCs and HSCs promotes
inﬂammation and ﬁbrogenesis. In addition, FC accumulation in liver mitochondria induces mitochondrial dys-
function, which results in increasing production of reactive oxygen species, and triggers the unfolded protein re-
sponse in the endoplasmic reticulum (ER) causing ER stress and apoptosis. These events create a vicious circle
that contributes to the maintenance of steatosis and promotes ongoing hepatocyte death and liver damage,
which in turn may translate into disease progression. In the present review we summarize the current knowl-
edge on dysregulated cholesterol homeostasis in NAFLD and examine the cellular mechanisms of hepatic FC tox-
icity and its contribution to ongoing liver injury in this disease. The therapeutic implications of this knowledge
are also discussed.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
1.1. Concept and clinical spectrum of non-alcoholic fatty liver disease
(NAFLD)
The acronym non-alcoholic fatty liver disease (NAFLD) is an umbrel-
la termused to describe a clinicopathological entity deﬁned by the pres-
ence of a spectrum of hepatic histopathological changes ranging from
non-inﬂammatory intracellular fat deposition (isolated steatosis) to
non-alcoholic steatohepatitis (NASH), with the latter being character-
ized by steatosis, necro-inﬂammatory changes and various degrees of
liver ﬁbrosis [1,2]. Currently, NAFLD is recognized as the most common
form of liver disease worldwide affecting between 25 and 30% of the
general population [3,4]. Notably, NAFLD is highly prevalent among
overweight and obese patients and in subjects with type 2 diabetes
(T2DM) [5,6]. Moreover, NAFLD is strongly associated with the featuresólica de Chile, Departmento de
330024 Santiago, Chile.
vana.zanlungo@gmail.comof metabolic syndrome, and the hepatic manifestation of this cluster of
features linked to an increased cardiometabolic risk [7,8]. A clinically
relevant aspect of NAFLD is that a variable proportion of patients,mainly
thosewith NASH, exhibit an increased liver-relatedmortality due to the
progression to cirrhosis and its associated complications, including he-
patocellular carcinoma [9]. In fact, recent data shows that NASH is ex-
pected to become the leading cause of liver transplantation by 2020
[10]. Finally, NAFLD has been also linked to an increased risk of incident
T2DM and cardiovascular disease [9,11].
Aspects related to the transition from isolated steatosis to NASH, the
progressive form of the disease, are key issues in the study of NAFLD.
However, factors involved in the development of more aggressive
forms of the disease remain only partially unveiled [12]. Recognition
of these factors is important for the identiﬁcation of potentially useful
therapeutic targets [13,14]. In addition to well-known factors involved
in NASH pathogenesis and progression (i.e., degree of obesity, magni-
tude of insulin resistance (IR), adipokine imbalance, excessive dietary
fructose intake and ongoing oxidative stress driven by lipotoxic metab-
olites), emerging experimental and human data suggest that disturbed
hepatic cholesterol homeostasis and free cholesterol (FC) accumulation
are relevant to the pathogenesis of NASH [15,16]. In the present review,
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anisms of cholesterol toxicity, and we examine how alterations in cho-
lesterol homeostasis may promote hepatic cholesterol overload and
contribute to ongoing liver injury in NAFLD.
1.2. Pathogenesis of NAFLD/NASH
The precise pathophysiology of NAFLD is not fully understood [17].
Current concepts on disease pathogenesis are evolving as new informa-
tion is generated from both experimental models and human studies
[12]. Conceptually, NAFLD is generally conceived as a sequential process
consisting ﬁrst in steatosis development [i.e., pathological accretion of
lipids in the form of triglycerides (TGs)]. In some individuals, steatosis
may promote the occurrence of hepatocyte injury and death and subse-
quently induce localized inﬂammation and trigger a stereotyped hepatic
ﬁbrogenic response to injury [18,19]. The latter fuels the progression to
advancedﬁbrosis and cirrhosis [12,20]. Thus, key aspects of NAFLDpath-
ogenesis include the mechanisms of fat deposition in the liver cells and
the determinants of necro-inﬂammatory and ﬁbrotic changes, that can
drive disease progression [21]. Steatosis development is clearly related
to the occurrence of IR at the level of the hepatic, muscle and adipose tis-
sues [22,23]. Although the majority of NAFLD patients exhibit systemic
IR it is difﬁcult to determine which of the insulin sensitive tissues is
the primary site of IR in NAFLD [24]. This is a complex issue that faces
methodological problems to be solved since the precise assessment of
insulin resistance requires complex techniques such as the euglycemic
hyperinsulinemic clamp and the use of stable isotopes, which is cumber-
some [25]. Some recent lines of evidence suggest that hepatic IR, second-
ary to the accumulation of diacylglycerols (DAGs), may be the primary
pathogenic event [26], although this hypothesis remains controversial
[24]. The observation that the disease may recur after transplantation
[27] suggests that peripheral IR is a primary event. Based on this obser-
vation and additional existing data, the predominant view about
steatosis development is that an initial impaired peripheral insulin ac-
tion in white adipose tissue (WAT) would lead to an uninhibited lipoly-
sis that, in turn, produces an increased ﬂux of fatty acids (FAs) to the
liver andother organs. VisceralWAT is considered an important contrib-
uting source to the overﬂow of FA to the liver due to the direct drain of
its circulation to the portal vein [20,28] but the contribution of subcuta-
neous fat is also substantial due to the size of this depot particularly in
obese subjects [29]. Lipolysis in adipocytes is a complex and tightly reg-
ulated phenomenon that involves neuroendocrine signals resulting in
the activation of lipolytic enzymes that drive lipid mobilization.
Among these enzymes, hormone sensitive lipase (HSL) and adipocyte
triacylglycerol lipase are the key enzymes for lipolysis initiation [30]. De-
tails of regulatory mechanisms of adipocyte lipolysis are beyond the
scope of the present review and can be found elsewhere [31,32]. Sufﬁce
to say that insulin by regulatingHSL limits the liberation of FA fromWAT
and rather induces de novo lipogenesis in this tissue. Thus, if IR is pres-
ent lipolysis becomes hyperactivated in adipocytes, resulting in an in-
creased release of FA to plasma.
The reasons of IR development inWAT are complex and involve a se-
quence of events that determine a phenomenon known as adipose tissue
dysfunction that in turn determines local IR and dysregulation of other
physiological functions of WAT such as the secretion of adipokines [33].
Brieﬂy, in conditions of excessive calorie intake, adipocytes become hy-
perplastic, which is associated to a relative local hypoxia and the devel-
opment of WAT stress and autophagy followed by the occurrence of
immune cell inﬁltration and inﬂammation [33,34]. This dysfunctional
and injured WAT become resistant to insulin action and uninhibited li-
polysis occurs. Dysregulated adipokine secretion is characterized by the
secretion of a proinﬂammatory and atherogenic adipokine proﬁle with
decreased adiponectin (an insulin-sensitive adipokine) and increased
tumor necrosis factor-α (TNF-α, a cytokine that promotes IR both locally
and systemically) [33,35]. Thus, uninhibited lipolysis of triacylglycerol in
WAT determines an overﬂow of nonesteriﬁed FAs to the liver. In fact, ithas been estimated that approximately 60% of TGs present in the liver
in patients with NAFLD originate from WAT [36,37]. Uptake of FAs
from plasma in the liver is mediated by fatty acid transport proteins
(FATPs) and the fatty acid translocase FAT/CD36. Both FATP2 and
FATP5 are highly expressed in hepatocytes and FATP5 knockout mice
are protected against liver fat accumulation. However, no evidence of a
relevant role in humans is available [38]. On the other hand, FAT/CD36
has been found upregulated in both human and experimental NAFLD
[39,40], which may contribute to liver fat overload. Once inside the
liver FAs are bound by cytosolic fatty acid-binding proteins (FABPs).
Mice deﬁcient in FABP are resistant to diet-induced hepatic steatosis
[41] but the role of these proteins in human NAFLD is not known.
In addition to the overﬂow of FAs to the liver fromWAT, enhanced
de novo hepatic lipogenesis is also recognized as an important contrib-
utor to TG accumulation in liver cells [42,43]. Studies using isotope la-
beling have shown that this pathway accounts for 25% of hepatic TGs
in NAFLD patients [36,37]. Increased de novo lipogenesis is driven by
compensatory hyperinsulinemia present in IR states [42]. In fact, insulin
increases the hepatic activity of critical transcription factors, such as
sterol regulatory element-binding protein-1c (SREBP-1c), carbohydrate
response element-binding protein (ChREBP) and peroxisome
proliferator-activated receptor (PPAR)-γ, which are the major drivers
of hepatic de novo lipogenesis [42,44]. Stimulation of this pathway by
dietary components, such as fructose and high-fructose corn syrup,
has been proposed as a contributing factor to the development and se-
verity of NAFLD [45]. However, this idea has been disputed by other
studies showing that the reported associations of fructose with clinical
or histopathological evidence of NAFLDmay bemore attributable to ex-
cess energy than fructose itself [46,47].
The precise role of additional pathways of FA metabolism in NAFLD,
such as impaired hepatic FA oxidation (whichwould lead to a reduction
in FA utilization) and/or impaired synthesis or secretion of very low-
density lipoproteins (VLDLs) (which would lead to a decrease in the
export of TG from the liver), is still notwell deﬁned. In the case of FA ox-
idation although data support the presence of mitochondrial dysfunc-
tion in NAFLD, data on the role of impaired of FA oxidation in this
setting is inconclusive [48]. With regard to dysregulation of VLDL pro-
duction and secretion, it has been shown that individuals with NAFLD
exhibit and increase in VLDL secretion [49] likely as a compensatory re-
sponse to intracellular TG accumulation. However, the increase in he-
patic TG export through this pathway seems to be insufﬁcient to
normalize the elevated hepatic TG content.
Once steatosis is established, liver cell damage may occur with ac-
companying inﬂammation and/or ﬁbrosis consistent with NASH [19,
20,50]. Multiple factors, including worsening IR, insults from the gut
[bacteria derived products that can activate Toll-like receptors (TLRs)]
in both hepatocytes and resident macrophages and/or the adipose tis-
sue (leading to saturated FA-induced lipotoxicity), promote hepatic
cell injury and death through a variety of mechanisms [51–53]. Al-
though in some cases steatosis precedes NASH, it is also possible that
steatosis develops with other features of NASH simultaneously. In fact,
it has been proposed that subjects with bland steatosis and NASH
could belong to different subsets of individuals with separate histologi-
cal features and pathophysiology [54–56].
1.3. Modulators of liver injury in NAFLD
Factors that trigger ormodulate liver damage in the setting of NAFLD
can help to identify potentially useful therapeutic targets [13,14]. In-
deed, correction and management of known NASH-related factors in-
volved in pathogenesis and progression, such as the degree of obesity,
the severity of IR, the coexistence of T2DM, the occurrence of oxidative
stress and excessive dietary energy and fructose intake, are the current
focus of NAFLD/NASH treatment [14,57,58]. In addition, identiﬁcation of
genetic factors that determine risk of disease occurrence or progression
may help to identify individuals who may experience associated
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NAFLD but the common variant p.I148M of the enzyme adiponutrin
[also known as Patatin-like phospholipase domain-containing 3
(PNPLA3)] gene has emerged as a one of the major genetic determi-
nants of both steatosis and steatohepatitis, and it has been linked to ﬁ-
brosis, cirrhosis, and hepatocellular cancer [60]. Recently, another
common non-synonymous polymorphism in the TM6SF2 gene
(rs58542926 c.449 CNT, p.Glu167Lys) has been linked to advanced he-
patic ﬁbrosis and cirrhosis [61]. The underlying mechanisms by which
these gene variants inﬂuence liver injury remain to be elucidated.
A signiﬁcant body of work has recently uncovered information on the
role of novel factors that may modulate liver injury in NAFLD/NASH.
Among them the contribution of innate and adaptive immunity with he-
patic resident macrophages (Kupffer cells, KCs) sensing danger signals
and recruiting inﬂammatory cells [62] leading to sterile inﬂammation,
the occurrence of a disrupted intestinal epithelial barrier in the presence
of microbiome dysbiosis [63,64] and activation of TLRs [65]. These mech-
anismshavebeen suggested to contribute to disease progression inNASH.
Importantly, the activation of pattern recognition receptors results in the
activation of the inﬂammasome, a multimolecular cytosolic protein com-
plex, which promotes local production of pro-inﬂammatory cytokines
[66–68] and contributes to inﬂammation and injury. In addition, path-
ways regulating ﬁbrogenesis are important in NASH progression [19]. Ac-
tivation of hepatic stellate cells (HSCs) is a key event. HSCs express a
myriad of receptors that upon stimulation promote differentiation of
this cell type to cellularmatrix-production cells [69,70]. These receptor–li-
gand interactions and associated intracellular signaling pathways
(e.g., the renin–angiotensin–aldosterone system [71] and endothelin-,
farnesoid X receptor (FXR)- or PPAR-associated pathways) [72–74] are
therefore important for modulating ﬁbrosis progression in NASH and
may serve as therapeutic targets [75,76].
Information regardingwhich toxic lipids cause liver damage inNAFLD/
NASH is limited. The mechanism(s) responsible for the accumulation and
maintenance of an excessive amount of intrahepatic fat remain only par-
tially known and, as mentioned above, involve an imbalance between the
hepatic production of TGs (primarily derived from plasma FAs delivered
to the liver fromWAT) and the removal of intrahepatic TGs. TGs are pri-
marily exported from the liver within VLDLs [37,49,77,78] but a fraction
of the FAs contained in TGs can be secreted in the form of phospholipids
through the bile [79]. Observations from experiments inhibiting hepatic
TG synthesis and patients with hypobetalipoproteinemia, which does
not progress to cirrhosis despite massive steatosis, suggest that hepatic
TG accumulation is not toxic per se, but rather protects the liver by buffer-
ing the accumulation of lipotoxic TG precursors [80–82]. Interestingly, the
exposure of cultured cells to unsaturated FA resulted in a signiﬁcant in-
crease in TG content without an associated decrease in cell viability. In
contrast, cells incubated with saturated FAs showed a signiﬁcant increase
in apoptotic death in conjunction with an absence of TG accumulation
[83]. Saturated FAs can induce hepatocyte cell death by directly activating
Jun N-terminal kinase (JNK) and mitochondrial pathways. In addition to
saturated FAs, other toxic lipid molecules may be responsible for liver
damage, including DAGs, ceramide and sphingosine [37,84–89]. In addi-
tion to the abovementioned role of direct toxicity of saturated FAs in
NAFLD, recent experimental and human evidence points to a role of al-
tered cholesterol homeostasis and hepatic FC accumulation in the patho-
genesis and progression of NAFLD/NASH [90–100]. The recognition of
intracellular cholesterol accumulation as a modulator of liver injury in
NASH is relevant as it could be exploited as a therapeutic target. Therefore,
in the following sections, we address the underlyingmechanisms causing
FC accumulation and the relevance of FC accumulation in NAFLD/NASH.
2. Hepatic cholesterol accumulation in NAFLD: relevance
and mechanisms
Different lines of evidence have demonstrated the occurrence of he-
patic cholesterol accumulation in NAFLD. Seminal studies from Puriet al. using lipidomic analysis of liver biopsies from NAFLD patients
have shown accumulation of FC without an increase in cholesterol es-
ters (CEs) in isolated steatosis and NASH subgroups [92]. More recent
studies have unequivocally demonstrated that hepatic FC accumulation
is a prominent feature of NAFLD that correlates with histological sever-
ity of the disease [90,94]. Also, epidemiological studies have identiﬁed
dietary cholesterol intake as a factor related to the risk and severity of
NAFLD [16,101–103]. Animal studies showed that experimental induc-
tion of hepatic FC accumulation promotes steatohepatitis and liver ﬁ-
brosis [95,97,98,104,105], and that correction of hepatic FC overload
improves liver disease severity in NASH [99,106–108]. Furthermore,
the potentially beneﬁcial effects of the lipid-lowering agent ezetimibe
in NAFLD/NASH may be mediated by a reduction in hepatic cholesterol
levels [109,110]. Thus, FC accumulation is a reproducible and relevant
phenomenon in NAFLD that has a signiﬁcant role inmodulating liver in-
jury and may be amenable to drug therapy.2.1. Regulatory mechanisms of cholesterol homeostasis in the liver:
alterations in NAFLD
The liver is a key organ involved in the regulation of cholesterol
metabolism and acquires cholesterol from de novo synthesis and
from all classes of plasma lipoproteins [111,112]. The synthesis of
cholesterol occurs in the endoplasmic reticulum (ER) and is strictly
regulated by the enzyme 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMGCR), which catalyzes the ﬁrst reaction of cholesterol
biosynthesis [111,112]. The uptake of cholesterol from lipoproteins
occurs through different surface proteins, including the low density
lipoprotein (LDL) receptor (LDLR) and the scavenger receptor class
B type I (SR-BI) [112,113].
Independent of its origin, hepatic cholesterol has several alternative
metabolic pathways: (1) excretion or efﬂux into the blood in the formof
VLDL or through ABCA1 to nascent high-density lipoprotein (HDL) par-
ticles, respectively; (2) excretion and uptake through bile via ABCG5/G8
andNiemann–PickC1-like 1 protein (NPC1L1), respectively; (3) deposi-
tion as CE and (4) substrate for bile acid (BA) synthesis [113]. Under
normal conditions, these pathways interact with each other tomaintain
cholesterol levels within a speciﬁc range. In addition, cholesterol must
be sorted and transported within the hepatocyte toward different re-
gions and organelles [114,115]. These complex and highly regulated
metabolic and trafﬁcking pathways involve multiple cholesterol meta-
bolic and transport-related genes whose gene expression is regulated
by the concerted activity of several transcriptional factors, including
the sterol regulatory element-binding protein 2 (SREBP-2), Liver X re-
ceptor alpha (LXR-alpha) and FXR [116,117].
Intracellular cholesterol synthesis is controlled by an elaborated
feedback mechanism dependent on the transcription factor SREBP-2,
which is bound to the membrane of the ER [118]. When cholesterol is
abundant, SREBP-2 remains in the ER. Low levels of intracellular choles-
terol cause SREBP-2 to be processed by proteases and its active core
travels to the nucleus to turn on the expression of genes containing ste-
rol responsive elements in their promoters, such as the LDLR and HMGR
genes [118].
BAs are essential for proper absorption of dietary lipids and regulate
the transcription of genes that regulate the metabolism of cholesterol
and BA [119–123]. The hepatic expression of cholesterol-7α-hydroxy-
lase (CYP7A1), the rate limiting enzyme for the synthesis of BA from
the classical pathway, is suppressed by increased BA levels and this
feedback mechanism is mediated by FXR [123,124]. Furthermore, the
selective uptake of high density lipoprotein CE via SR-BI [125], the intra-
cellular CE hydrolysis facilitated by neutral cholesteryl ester hydrolase
(nCEH) [126], and the canalicular routing of cholesterol by sterol carrier
protein 2 [127] for biliary excretion via adenosine triphosphate binding
cassette subfamily G member 5/8 (ABCG5/8) [128] are positively regu-
lated by FXR [129].
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generated during bile acid synthesis that are potent ligands of the LXR
[130,131]. Activation of LXRs induces the expression of several genes in-
cluding the gene encoding for CYP7A1 and those regulating reverse cho-
lesterol transport and cholesterol catabolism [132]. Both FXR and LXR
must heterodimerize with the 9-cis retinoic acid receptor (RXR) in
order to bind DNA and act as transcription factors. Thus, FXR and LXR
co-regulate the synthesis of bile salts and cholesterol homeostasis in he-
patocytes [132].
In addition to the transcription factors described above, another re-
cently described regulator, ﬁbroblast growth factor 19 (FGF19), a gut-
derived hormone or enterokine, has been found to play a role in the reg-
ulation of hepatic lipid metabolism and glucose and protein homeosta-
sis [11]. FGF19 is part of a complex enterohepatic feedback regulatory
mechanism involving activation of FXR by BA in the ileum that enhances
the gene encoding FGF19. Once produced, FGF19 is secreted into the
portal circulation to bind the FGFR4/b-klotho receptor complex in hepa-
tocytes [133]. Upon binding to its receptor, this hormone controls he-
patic metabolism by inhibiting BA and glucose synthesis. FGF19
inhibits BA synthesis through inhibition of CYP7A1 and blunts gluco-
neogenesis through a mechanism involving inactivation of the tran-
scription factor cAMP regulatory element binding protein (CREB)
[134]. In addition, FGF19 stimulates protein and glycogen synthesis
and FA oxidation [133,135].
Existing data support the concept that cholesterol homeostasis is ex-
tensively dysregulated in NAFLD and that alterations of hepatic choles-
terol pathways at different levels do promote FC accumulation in liver
cells (Fig. 1). In fact, hepatic cholesterol synthesis has been shown to
be increased in NAFLD as shown in studies assessing this pathway
using serum non-cholesterol sterols as surrogatemarkers of cholesterol
synthesis [136]. Moreover, several studies have shown that the expres-
sion and activity of HMGCR are increased in livers of NAFLD patients
which seem to be related to a decrease in HMGCR phosphorylation,
leading to an increased activity of the enzyme [90,137,138]. In addition,
increased hepatic levels of active SREBP2, which is the key protein reg-
ulating cholesterol synthesis,may also play a role since increased hepat-
ic FC levels and LDLR expression correlated with SREBP-2 induction in
NASH patients [94].
Lipoprotein metabolism is also dysregulated in NAFLD [139,140]. A
pattern of atherogenic dyslipidemia characterized by high concentra-
tions of plasma TG, low HDL cholesterol and small dense LDL particles
is frequently observed in NAFLD patients [141,142], which is related to
increased insulin-induced hepatic lipid synthesis and is associated
with disease severity [143]. Liver TG overload is associated to increased
VLDL secretion toward plasma [49]whichmay determine an increase in
LDL due to cholesteryl ester transfer protein exchange [139] which is
then recaptured in the liver by LDLR-mediated endocytosis. Of note,
LDLR has been shown to be upregulated in some experimental models
of NASFLD/NASH [98], which could contribute to hepatocyte cholesterol
overload. However, a recent human study found that the hepatic LDLR
expression was decreased and plasma LDL concentrations increased in
subjects with NAFLD [90]. Thus, further studies are required to deter-
mine if LDLR up- or down-regulation is a common and relevant alter-
ation in the liver of NASH/NAFLD patients.
Disturbed efﬂux of cholesterol through ABCA1 to extracellular
apolipoprotein AI could also contribute to increase hepatocyte cho-
lesterol content. In vitro studies in HepG2 cells treated with unsatu-
rated FA have shown decreased ABCA1 protein levels due to the
induction of its protein degradation. This correlates with decreased
hepatic ABCA1 protein levels in experimental NASH [144]. In addi-
tion, ABCA1 overexpression in mice resulted in an increase in choles-
terol efﬂux and decreased cellular cholesterol, FA and TG levels
[145]. These data suggest that in NAFLD/NASH a decrease in ABCA1
protein expression may contribute to an increase in lipid storage in
hepatocytes although more data is needed to establish the its role
in NAFLD/NASH.The role of reduced biliary cholesterol excretion in hepatic cholester-
ol loading in NAFLD has also been examined. Mice lacking the ABCG5/8
sterol transporter exhibit reduced biliary cholesterol secretion and are
more susceptible to steatosis, hepatic IR, and loss of glycemic control
when fed a high-fat diet [146]. Other genetic models of hepatic steatosis
also exhibit a decreased biliary cholesterol secretion [147,148]. Interest-
ingly, promotion of biliary cholesterol secretion using adenoviral
vectors encoding ABCG5 and ABCG8 restores glycemic control and re-
duces plasma TG in diabetic mice [149]. However, data from other
models is conﬂicting as has been also shown that hepatic IR directly pro-
motes biliary cholesterol secretion [150], which would also explain the
strong association between NAFLD and cholesterol gallstone disease
[151]. However, it is not yet clear whether NAFLD is pathogenetically
linked to gallstone formation or whether the presence of gallstones is
a marker of the presence of metabolic factors that promote NAFLD de-
velopment [152]. Thus, currently available data with regard to biliary
cholesterol in NAFLD and its link with gallstone disease from both ani-
mal models and epidemiological studies is conﬂicting and need further
clariﬁcation.
Other potential mechanisms for cholesterol accumulation in NAFLD
can be postulated from published data, particularly from the work of
Min et al. These authors extensively assessed the expression of choles-
terol metabolic genes in NAFLD [90]. Decreased expression of the cho-
lesterol efﬂux gene, ABCG8, in the livers of NAFLD patients supports
the possibility of decreased FC efﬂux in fat-laden hepatocytes [90]. In
addition, the authors reported an increased expression of hepatic neu-
tral cholesterol ester hydrolase (nCEH) in NAFLD patients, which may
contribute to the increase in hepatic FC content by inducing CE hydroly-
sis and returning cholesterol to the intrahepatic FC pool [90] (Fig. 1). In
this study, patients with NAFLD and NASH had a decreased expression
of CYP7A1 and CYP27A proteins, which are both involved in the catab-
olism of cholesterol to BA. Thus, decreased cholesterol biotransforma-
tion would also contribute to intrahepatic cholesterol accumulation
[90]. Interestingly, decreased hepatic expression of CYP7A1was also ob-
served in a rat model of NASH induced by increasing the cholesterol
content of the diet [153]. Of note, insulin seems to have dual effects on
CYP7A1 gene transcription since while physiological concentrations of
insulin upregulate the human CYP7A1 gene, prolonged insulin treat-
ment induces SREBP-1c, which inhibits CYP7A1 gene transcription
[154]. Thus worsening IR and hyperinsulinemia may contribute to re-
duce CYP7A1 activity.
The accumulation of FC in NASHmay be related to increased intesti-
nal cholesterol absorption. Although indirect assessment of the latter in
humans using surrogate markers has shown that intestinal absorption
of cholesterol is actually decreased [136], experimental data indicate
that inhibition of this pathway by NPC1L1 using ezetimibe is beneﬁcial
in NAFLD [155] (Fig. 1) reducing FC accumulation in the liver [99,109,
156]. However, a recent trial examining the efﬁcacy of ezetimibe versus
placebo in reducing liver fat and improving liver histology in patients
with biopsy-provenNASH showed negative results [33]. Further studies
are needed to conﬁrm this ﬁnding.
Recently, several studies have identiﬁed alterations of miRNA pro-
ﬁles associated with NAFLD and NASH [32,157–161]. In fact, increased
mRNA levels and enzyme activity of HMGCR in patients with NAFLD
and NASH [90,162] are related to increased levels of the microRNA
miR-34a, which inhibits sirtuin-1 expression, a protein with histone
deacetylase activity, and decreases levels of phosphorylated HMGCR
[90]. Evidence from animal models indicates that NASH development
is accompanied by prominent changes in miRNA expression, including
miR-34a [158,163]. These data suggest that miR-34a changes may con-
tribute to the development of NASH. In addition, other microRNA, miR-
122, the most abundant hepatic miRNA, was shown to be strongly
downregulated in NASH patients [158]. Interestingly, silencing of miR-
122 led to an initial increase in mRNA levels of its target genes, among
them Hmgcr and Srebp-2, by 24 h followed by a decrease by 48 h in
HepG2 cells. This was correlated with an increase in the protein levels
Fig. 1. Cholesterol homeostasis dysregulation contributes to free cholesterol accumulation in NAFLD. Cholesterol homeostasis is extensively dysregulated at different levels in NAFLD and
thus promotes free cholesterol (FC) accumulation. Multi-level changes occur in the liver, including the activation of cholesterol biosynthetic pathways, increased cholesterol de-esteriﬁ-
cation, and attenuated pathways in cholesterol export and BA synthesis. These changes may contribute to FC accumulation in the setting of NAFLD. This ﬁgure depicts lipoproteins, pro-
teins, miRNAs or pathways whose levels are increased or decreased and/or up- or downregulated (arrows) in plasma, hepatocytes and enterocytes. In plasma, NAFLD patients typically
exhibit a pattern of atherogenic dyslipidemia characterized by high concentrations of VLDL, and low HDL and apoAI levels. Decreased apoAI levels correlatewith a decrease in ABCA1 pro-
tein levels. These decreasesmay contribute to FC accumulation in the liver. In addition, the increased expression and activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) cor-
relate with increased levels of miR-34a, and it is a contributing factor to increased FC synthesis. Microsomal sterol 7a hydroxylase (CYP7A1) and mitochondrial sterol 27-hydroxylase
(CYP27A) catalyze the synthesis of bile acids (BAs) using classic and acidic pathways, respectively. In NAFLD, both enzymes show decreased levels in the liver, thus limiting cholesterol
degradation. Another factor that contributes to hepatic FC accumulation is the increased expression of neutral cholesteryl ester hydrolase (nCEH) through induction of CE hydrolysis
and the return of cholesterol to the intrahepatic FC pool. Fibroblast growth factor-19 (FGF-19) is an ileum-derived enterokine that also inﬂuences cholesterol metabolism. This hormone
signals the liver through the FGFR4/β-klotho receptor to inhibit CYP7A1; furthermore, FGF-19 was found to be decreased in NAFLD patients. The inset shows the relevant regulation gene
pathways for cholesterol and BAmetabolism in hepatocytes and their dysregulation induced by NAFLD (increased or decreased, shownwith arrows). An increase in SREBP-2 induces the
expression of theHMGCR gene, promoting synthesis and FC accumulation. In addition, FXR down-regulation correlateswith a decreased expression of the Abcg8 gene in the liver of NAFLD
patients. This gene encodes for a half-transporter that promotes biliary excretion and limits the intestinal absorption of cholesterol, and the down-regulation of this gene contributes to
hepatic cholesterol loading. In the enterocyte, ezetimibe use confers resistance to NAFLD in animal models. This effect is likely mediated by the inhibition of the Niemann–Pick C1-like 1
(NPC1L1) transmembrane protein localized at the apical membrane of enterocytes, which promotes cholesterol absorption. Thus, targeting this pathwaymay signiﬁcantly contribute to a
decrease in FC accumulation in the liver and potentially reduce liver damage.
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dictory data for thismiRNA. In fact,miR-122was also found to be upreg-
ulated throughout the progression of NAFLD in a rat model [159]. In
addition, evidence in murine studies showed that silencing of miR-122
in vivo by antagomirs results in a 25%–30% reduction of plasma choles-
terol levels and decreased expression of several hepatic genes involved
in the biosynthesis of cholesterol, such as 3-hydroxy-3-methylglutaryl-
Coa synthase 1 (Hmgcs1), Hmgcr and 7-dehydrocholesterol reductase(Dhcr7) [164]. Similarly, antisense-based silencing of miR-122 in-
duced a signiﬁcant decrease in FA and cholesterol biosynthesis and
an increase in the FA β-oxidation pathway in mice fed a high fat
diet [165]. In conclusion, the effect of miR-122 on cholesterol biosyn-
thesis is contradictory and it is difﬁcult to establish its relevance and
role in the progression of liver disease and additional studies are
needed to determine if impairment of miR-122 signaling contributes
to NAFLD.
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miR-21, was found in patients with NAFLD.miR-21 decreased the levels
of TG, FC and total cholesterol in an in vitromodel of NAFLD, and this ef-
fect was attenuated by Hmgcr overexpression [166]. Collectively, avail-
able data suggest the existence of a pathogenic role of miRNAs in
NAFLD. However, further studies are necessary to unveil the basis of
miRNA dysregulation in NAFLD as well as the exact contribution of spe-
ciﬁc microRNAs and the underlying mechanisms that contribute to
NAFLD pathogenesis. Notably, selected miRNAs may be used as bio-
markers of disease in the near future [32,161].
In summary, several metabolic pathways involving hepatic choles-
terol homeostasis are dysregulated in NAFLD. A recent detailedmolecu-
lar analysis of liver samples from NAFLD patients revealed signiﬁcant
changes, including activation of cholesterol biosynthetic pathways (in-
creased SREBP2 processing and HMGCR activity), increased cholesterol
de-esteriﬁcation (increased nCEH activity), and attenuated pathways in
cholesterol export (decreased expression of ABCG8) and BA synthesis
(decreased expression of CYP7A1) (Fig. 1). These changes resulted in in-
creased FC levels that may directly promote the hepatocellular injury
observed in NAFLD (see Section 2.3) [90].
2.2. Alterations in intracellular cholesterol transport
In addition to the aforementioned changes in cholesterol metabolic
pathways, alterations in the intracellular cholesterol transport have
also been described in NAFLD and NASH. In fact, the study of alterations
of intracellular sterol binding and transfer proteins, FC accumulation
and delivery to speciﬁc cellular compartments in NAFLD has gained at-
tention in the recent years [16,162].
Caveolin-1,which is themain structural protein of caveolae, exhibits
cholesterol-binding and transport activity and has been suggested to
play a role in the regulation cellular cholesterol homeostasis [167]. In-
terestingly, a signiﬁcant increase in the expression of caveolin-1 around
and within the lipid droplets as well as in the inner membrane of mito-
chondriawas found in amurinemodel of liver steatosis created by feed-
ing adult rats a choline-deﬁcient diet for 14 days [168]. Moreover,
increased levels of caveolin-1 mRNA and protein were found in a
NAFLDmodel after feeding C57BL/6micewith a high fat and cholesterol
diet for 14 weeks [169]. In this study, caveolin-1 localization was al-
tered, and the levels of this protein were increased in lipid droplets
and mitochondria. These data suggest that the expression and distribu-
tion of caveolin-1 are altered during abnormal hepatic lipogenesis and
involves the mitochondria of steatotic hepatocytes.
Niemann–Pick C1 and C2 proteins, NPC1 and NPC2, are involved in
the trafﬁcking of endocytosed lipoprotein cholesterol from the
endolysosomal compartment to the rest of the cell [170,171]. A deﬁcien-
cy in NPC1 or NPC2 is responsible for Niemann–Pick type C disease,
which is a rare neurovisceral disorder characterized by FC accumulation
in most tissues, including the liver [170,171]. Interestingly, decreased
NPC1 in mice is associated with weight gain and metabolic features as-
sociated with IR, including hepatic steatosis and hyperinsulinemia [172,
173]. In humans, NPC1 single nucleotide polymorphisms (SNPs) have
been associated with obesity and IR in European populations [174,175].
A family of proteins containing steroidogenic acute regulator
(StAR)-related lipid transfer (START) domains involved in cholesterol
trafﬁcking also seem to be particularly relevant [176]. The StAR protein
facilitates cholesterol movement from intracellular stores to the mito-
chondria of steroidogenic tissues stimulating steroid hormone synthesis
[177]. Interestingly, mRNA levels of StAR were increased 7- and 15-fold
in steatosis and NASH patients [94]. The closest StAR homologue is a
protein known as MLN64 (STARD3), which is highly expressed in the
liver [178] and is localized in the same compartment as NPC1 [179]. In-
terestingly, other members of the family, including StARD4 and StARD5
are regulated by SREBP-2 and ER stress [180]. Importantly, these factors
are also involved in the pathogenesis and progression of NASH. The rel-
evance of the sterol trafﬁcking capacity of StAR andMLN64 in regulatinghepatic cholesterol metabolism and transport to speciﬁc cellular
compartments, such as the mitochondria, is further discussed in
Section 2.3.3.
The oxysterol-binding protein (OSBP) family is formed by OSBP and
various evolutionary conserved OSBP-related proteins (ORPs) and con-
stitute a conserved family of lipid binding/transfer proteins (LTP) in eu-
karyotes [181]. OSBP is a cytosolic protein that has been implicated in
the regulation of cellular cholesterol, sphingomyelin, and oxysterol
transport (reviewed in [182]). Although no direct link has been provid-
ed betweenmembers of the ORP family and NAFLD, ORP8, has been im-
plicated in cholesterol metabolism and IR [181]. Silencing of ORP8
expression in THP-1 macrophages induced the transcription of ABCA1
and consequently increased cholesterol efﬂux [183]. In contrast, ORP8
overexpression in the liver of mice resulted in a reduction of plasma
and liver tissue lipid levels and down-regulation of the active, nuclear
forms of SREBP-1 and -2 [184]. In addition, ORP8 silencing impaired
insulin's ability to regulate AKT phosphorylation and downstream ki-
nase signaling in liver cells, and its expression was reduced in obesity
via a miRNA143-dependent pathway [185].
In summary,multiple pathways of cholesterol intracellular transport
may participate in NAFLD pathogenesis and progression. However, the
exact contribution of each of these pathways remains unclear.
2.3. FC and liver damage in NAFLD: potential mechanisms
As detailed above, cholesterol accumulation, and particularly in-
creased FC, seems to play an important role in liver injury in the setting
of NAFLD. However, although it has been found that FC directly causes
apoptosis and necrosis in hepatocytes [186], the precise mechanisms
of FC lipotoxicity in NASH are still incompletely delineated. Given the
fact that inﬂammation and ﬁbrosis development in the liver involves
the participation of non-parenchymal cells (i.e. KCs and HSCs) FC accu-
mulation in these cells may play a role in triggering injury. Also, speciﬁc
subcellular sites of FC accumulation in hepatocytesmay also be relevant
to promote either mitochondrial dysfunction or ER stress. Current evi-
dence on these topics is summarized below.
2.3.1. FC and activation of Kupffer and stellate cells
KCs are the resident macrophages in liver tissue that prevent harm-
ful endotoxins present in the portal vein from entering into the circula-
tion and are responsible for clearance of exogenous particulates and
immunoreactive material that is perceived as foreign and harmful
[187]. The functions of KC are precisely controlled to avoid an uncon-
trolled inﬂammatory response.
Increased evidence suggests that inﬂammationmediated byKCs is of
critical importance in the development of NASH Thus, using chemicals
to delete KCs has been demonstrated to alter the release of pro-
inﬂammatory cytokines and alleviate hepatocellular damage [188,
189]. Additionally, phagocytic dysfunction of KCs can accelerate inﬂam-
matory necrosis during hepatocyte fat accumulation [190]. Interesting-
ly, recent studies have implicated cholesterol accumulation in KCs in
inﬂammation animal models of NASH [191,192]. As expected, a high-
fat diet with cholesterol (HFC) induced hepatic inﬂammation and
foamy KCs in LDL receptor-deﬁcient and apolipoprotein E2 knock-in
mouse models that was found to be linked to increased plasma VLDL
cholesterol levels [193]. Interestingly, omitting cholesterol from the
HFC diet lowered plasma VLDL cholesterol and prevented the develop-
ment of hepatic inﬂammation and foam KCs [193]. C57Bl/6 mice fed a
high fat high cholesterol (1%) diet developed NASH and showed accu-
mulation of cholesterol crystals in KCs and increased inﬂammasome
activation [194]. Cholesterol crystals have been implicated in the activa-
tion of the inﬂammasome and macrophages in atherosclerotic lesions;
thus, these ﬁndings suggest that a similar process may occur in NASH
[195,196]. These ﬁndings strongly suggest that cholesterol metabolism
alterations may be relevant to KC activation in NAFLD/NASH. However,
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HSCs, also called lipocytes, are one of the inherent liver
nonparenchymal cell types located in the Disse space between hepato-
cytes and sinusoidal endothelial cells. In the normal liver, HSCs are in a
‘quiescent’ state [197]; however, when the liver is injured by viral infec-
tion or hepatic toxins, HSCs are activated and acquire features that are
relevant for the development of ﬁbrogenesis [197–199]. Interestingly,
recent evidence from animal models indicates that the major cause of
accelerated liver ﬁbrosis involved FC accumulation in HSC [200]. Several
mechanisms have been proposed to explain the relationship between
FC accumulation and ﬁbrosis in HSC. FC accumulation in HSC increases
Toll-like receptor 4 protein (TLR4) levels by suppressing the endosomal-
lysosomal degradation pathway of TLR4 and thereby downregulating
bone morphogenetic protein and activin membrane-bound inhibitor
(Bambi). Consequently, HSCs may become sensitized to transforming
growth factor β (TGFβ), resulting in HSC activation and progression of
liver ﬁbrosis [96]. Recent evidence indicates that ACAT1mediates liver ﬁ-
brosis by regulating FC accumulation in HSC; therefore, the regulation of
ACAT1 activity in HSCs could be a target for the treatment of liver ﬁbrosis
[201]. In summary, KC aswell asHSC accumulates FC,which activates cas-
cades thatmay contribute to liver inﬂammation andﬁbrosis inNAFLDand
NASH.
2.3.2. The unfolded protein response
The ER is the intracellular organelle responsible for the synthesis and
processing of proteins [202,203].Moreover, the ER controls cellular cho-
lesterol levels through pathways that sense the level of cholesterol or
cholesterol derivatives within the ER membrane itself and relay signals
controlling cholesterol synthesis and clearance [204]. Conditions that
impair ER protein homeostasis (proteostasis) or change the protein
folding capacity of the ER can lead to ER stress and induce the unfolded
protein response (UPR) [205–209]. The UPR is induced through the ac-
tivation of three transmembrane ER stress sensing kinases; PKR-like eu-
karyotic initiation factor 2 kinase (PERK), activating transcription factor
6 (ATF6) and inositol requiring 1 α(IRE1α), which aim to restore nor-
mal ER function [210]. These 3 proteins induce a signaling cascade
that brieﬂy consist in: i) PERK mediated phosphorylation of eukaryotic
initiation factor 2a (eIF2α) that leads to transient attenuation of transla-
tion but selective translation ofmRNAs containing upstreamopen read-
ing frames, such as activating transcription factor 4 (ATF4). Increased
transcription and translation of GADD34 subsequently lead to de-
phosphorylation of eIF2a and resumption of translation; ii) activation
of IRE1a that leads to the splicing of XBP1 generating the XBP1s tran-
scription factor; and iii) cleavage and activation of transcription factor
6 (ATF6), which in conjunction with ATF4 and XBP1s lead to transcrip-
tional activation of a number of gene targets related to protein folding
and ER-associated degradation [210].
Interestingly, the feedback inhibitory pathway comprising GADD34
mediated eIF2-α de-phosphorylation prevents the initiation of apopto-
tic and inﬂammatory pathways. If the cellular stressor exceeds the ER's
ability to restore normal ER function or the feedback inhibitory mecha-
nisms are inadequate, inﬂammatory and apoptotic pathways are initiat-
ed via the activation of protein kinases such as JNK [210].
Variable degree of UPR activation in NAFLD and NASH has been re-
ported. Livers from NAFLD and NASH were characterized by increased
phosphorylation of eIF2a, whereas several other markers of ER stress
were not increased, including ATF4 mRNA and protein, GADD34
mRNA and unspliced XBP1 mRNA. Livers from NASH subjects were ad-
ditionally characterized by a reduction in the amount of XBP1s and in-
creased phosphorylation of JNK [211]. Dysregulation of the UPR has
also been observed in db/db mice with diet-induced steatohepatitis
which presented an inadequate activation of recovery pathways
(GADD34, XBP-1(s)) and accentuated activation of injury pathways re-
lated to persistent eif2-α phosphorylation (ATF4, JNK, and nuclear fac-
tor kappaB (NF-κB)) [212]. Interestingly, pharmacologic JNK inhibitionattenuated UPR and downstream inﬂammatory signaling although it
did not prevent the development of diet-induced steatohepatitis
[212]. These results suggest that JNK is a relevant player in the contribu-
tion of the UPR-ER stress transduction pathway to the pathogenesis of
NAFLD. Supporting this idea, JNK signaling is also activated, as previous-
ly mentioned by saturated FA, and in conditions such as obesity and al-
tered insulin signaling in liver and adipose tissue [213].
Existing data indicate that ER stress induces lipid dysregulation, and
hepatic lipid accumulation induces ER stress. Together, these factors
create a positive feedback loop, which may stimulate the development
of hepatic NASH [214,215]. Accordingly, growing evidence suggests
that chronic ER stress induces numerous intracellular pathways that
can lead to hepatic steatosis, systemic inﬂammation, and hepatocyte
cell death. All of these processes are known to be important in the path-
ogenesis of NAFLD [210–212,216,217]. Moreover, increasing evidence
indicates that accumulation of cholesterol in the ER membrane induces
ER stress, apoptosis [218,219] and loss of the sarco/ER calcium ATPase
(SERCA)-mediated calcium homeostasis, which is presumably achieved
by promoting the formation of an ordered ER membrane phase that
perturbs the SERCA structure [218] (Fig. 2). Other recent study revealed
that a regular diet enriched in cholesterol (2%) alone is sufﬁcient to in-
duce hepatic ER–FC accumulation independent of tissue cholesterol
concentrations [220]. Additionally, ER stress impairs cholesterol efﬂux
and synthesis in human hepatic cells via reduction of HMGCR activity,
and may reduce HDL biogenesis due to impaired hepatic ABCA1 func-
tion [221]. Taken together, these data strongly supports the contribu-
tion of the UPR–ER stress to the pathogenesis of NAFLD (Fig. 2).
Interestingly, mitochondria also present an UPR that is activated by
alterations in mitochondrial proteostasis, such as by the accumulation
of un-assembled or unfolded proteins in themitochondria [222]. The ac-
tivation of mitochondrial UPR leads to the expression of nuclear-
encoded genes such asmitochondrial chaperones and proteases that re-
establish mitochondrial proteostasis and is a key mechanism to main-
tain mitochondrial health [222]. Of note, the mitochondrial and ER
UPR share some of their transduction pathways in mammals, including
phosphorylation of eIF2α, which inhibits cytosolic protein translation
[222]. The relationship between cholesterol levels, mitochondrial UPR
and liver disease has not yet been addressed. However, the hepatic ex-
pression of genes related with mitochondrial UPR is altered in high fat
diet fed mice [223].
2.3.3. Mitochondrial dysfunction
Recent evidence indicates that the accumulation of cholesterol in
mitochondria results in mitochondrial dysfunction and impairment of
speciﬁc carriers, including the mitochondrial transport of GSH, through
alterations in the mitochondrial membrane order [224–226].
Mitochondria contain cholesterol in very low amounts when com-
paredwith other cellular compartments, such as the plasmamembrane,
and are highly sensitive to changes in membrane ﬂuidity induced by
cholesterol enrichment [227]. An increase in cholesterol mitochondrial
content induces decreases in ATP synthesis, which is mediated by ATP
synthase, and in the ATP/ADP exchange in the inner and outer mito-
chondrial membranes, which is mediated by the adenine nucleotide
translocase and the voltage dependent anion channel, respectively
[228–230].
Moreover, mitochondrial cholesterol content is relevant for the trans-
port of mitochondrial-reduced glutathione (mGSH), an essential antioxi-
dant that controls reactive oxygen species (ROS) generation and prevents
mitochondrial dysfunction and cell death (Fig. 2).mGSH is synthesized de
novo in the cytosol and transported by the mitochondrial membrane by
the 2-oxoglutarate carrier [231]. This carrier is highly sensitive to changes
inmitochondrialmembrane cholesterol content and ﬂuidity. In fact, it has
been found that cholesterol incorporation in isolated mitochondria de-
creases mGSH stores [224]. Decreased levels of the antioxidant mGSH
sensitize hepatocytes to oxidative stress and inﬂammatory cytokines.
The survival of the cell is dependent on mGSH because it protects
Fig. 2. Relevance of free cholesterol accumulation to liver damage in NAFLD/NASH. FC accumulation leads to liver injury in NASH/NAFLD through the activation of intracellular signaling
pathways that inﬂuence the major hepatic cells: Kupffer cells (KCs), stellate cells (HSCs) and hepatocytes. FC accumulation in KCs and HSCs correlates with their activation. Activation of
KCs causes the secretion of pro-inﬂammatory mediators (e.g., interleukin-6 and 8 and tumor necrosis factor-alpha [TNFα]) and pro-ﬁbrotic factors (i.e., transforming growth factor β
[TGFβ]) that inﬂuence neighboring cells and induce inﬂammation. In addition, high FC levels in HSCs upregulate Toll-like receptor 4 (TLR-4), a lipopolysaccharide receptor, and sensitize
HSCs to TGFβ. These changes result in HSC activation and increased liver ﬁbrogenesis. Finally, FC accumulation in hepatocytes induces itself lipid peroxidation and lipotoxicity leading to
cellular dysfunction and death. Among the speciﬁcmechanisms of hepatocyte damage, it has been shown that FC accumulation in themitochondria causesmitochondrial dysfunction and
induces an increase in reactive oxygen species (ROS); furthermore, FC overload in the endoplasmic reticulum (ER) triggers the unfolded protein response (UPR) and ER stress and apo-
ptosis through JNK activation. Notably, ROS and lipid peroxidation products are able to diffuse into the extracellular space affecting both KCs andHSCs. These events lead to a vicious circle
that causes continual liver damage, inﬂammation, and steatosis that ultimately leads to the progression to NAFLD.
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mitochondrial membrane permeabilization by proapoptotic bcl-2 family
members [227]. These proteins increase cell death and may contribute
to liver injury in fatty liver disease.
Multiple experimental models showed that FC accumulation in mi-
tochondria sensitizes hepatocytes to TNF-α leading to mGSH depletion
[95]. Moreover, recent studies in primary mouse hepatocytes loaded
with FC and incubated with LDL showed that mitochondrial cholesterol
deposition caused hepatocyte apoptosis and necrosis by activating the
JNK1 pathway [232]. These effects were accompanied by activation of
themitochondrial membrane pore transition, cytochrome c release, ox-
idative stress and ATP depletion [233].
The StAR protein has been proposed as a candidate protein mediat-
ing the increase in cholesterol transport to the mitochondria [16]. This
proteinwas originally described for its critical role mediating cholester-
ol ﬂux toward themitochondrial innermembranes for steroid synthesis
in steroidogenic tissues [234]. However, StAR is not only expressed in
steroidogenic tissues, such as the adrenal cortex and the gonads, but it
is also expressed in many other tissues, including the liver, and may
function as a mitochondrial cholesterol transport facilitator. As men-
tioned before, mRNA levels of StAR were increased several folds in
steatosis and NASH patients [94].
Another candidate protein mediating cholesterol transport to the
mitochondria in liver is MLN64. This protein is located in late
endosomes [179]. This speciﬁc localization suggests that MLN64 may
transport cholesterol derived from LDL. Furthermore, adenovirus-
mediated overexpression of MLN64 induces an increase in hepatic FC
that is associated with apoptosis and liver damage [235]. Additionally,
MLN64 overexpression causes an increase in mitochondrial cholesterol
content in the liver and correlates with decreased ATPase activity and
decreased maximal respiration rates (Balboa et al., unpublished obser-
vation). Knockdown of MLN64 by siRNA reduced cholesterol transportto themitochondrial innermembrane in bothwild-type and NPC1 deﬁ-
cient cells, demonstrating a signiﬁcant role for MLN64 in the mitochon-
drial delivery of cholesterol [236]. Interestingly, we found increased
MLN64 liver expression in NPC1-deﬁcient mice (Balboa et al., unpub-
lished observation), which show liver damage, and in mice with a cho-
lestatic hepatocyte injury induced by a diet high in CDCA, which is a
well-characterized model of apoptosis-related liver damage induced
by BA [235]. These data suggest that MLN64 plays a role in the response
of hepatic cells to different insults.
By contrast, recent studies in rats have shown that loss of hepatic ex-
pression of MLN64 induced by genetic obesity may contribute to the
pathogenesis of dyslipidemia and steatosis [237]. The authors also
showed that MLN64 overexpression increased lipidation of exogenous
apoA-I and facilitated the de novo biosynthetic pathways for neutral
lipids in hepatic cells lines. These effects potentiated TG accumulation
but possibly offered protection against lipotoxicity. The authors pro-
posed that MLN64 may increase circulating levels of HDL and protect
the liver against lipotoxicity.
Finally, JNK1 activation has been found as a relevant consequence
mitochondrial FC deposition in experimental models. Recent work
from Gan et al. [186] demonstrated that JNK1 drives mitochondrial
cell death pathways leading to release of high mobility group box 1
(HMGB1) protein which in turn activates TLR4 in neighboring hepato-
cytes thus promoting hepatocellular injury. This work is in agreement
with that of Li et al. examining the role of HMGB1 and TLR4 in the path-
ogenesis of NASH [238]. Thus, JNK1 and TLR4 seem to be relevant path-
ways in FC lipotoxicity that may be eventually amenable of modulation
with speciﬁc inhibitors [186].
In conclusion, the increase in mitochondrial FC content contributes
to mitochondrial dysfunction, sensitizes hepatocytes to cytokine signal-
ing and leads to mGSH depletion contributing to hepatocyte cell death
by apoptosis and necrosis (Fig. 2) [53,186]. Altered expression of
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crease inmitochondrial FC content, and JNK1 activation could be poten-
tial therapeutic targets in NAFLD.
3. Therapeutic perspectives
Data discussed above points to a relevant role of disturbed hepatic
cholesterol homeostasis and FC accumulation in NAFLD pathogenesis
and progression. In this setting, pharmacological modulation of dysreg-
ulated cholesterol metabolism pathways could represent an attractive
therapeutic aim. Several currently available drugs and new agents that
are either in development or being tested in clinical trials may be useful
to treat NAFLD/NASH due to their effects on cholesterol metabolism.
This issue is discussed in the following sections.
3.1. Cholesterol lowering agents
Reduction of intrahepatic cholesterol content can be achieved using
commonly used drugs, such as statins and ezetimibe, which are consid-
ered safe in patients with NAFLD [110,239]. Therefore, in addition to a
potential reduction in cardiovascular risk (i.e., coronary artery disease
remains themost common cause of death in these patients, and thema-
jority of patients have dyslipidemia) [142], management of dyslipid-
emia of NAFLD patients with statins, ezetimibe or a combination of
both drugs could have beneﬁcial effects on hepatic disease course
[240,241]. In experimental models statin administration decreases
hepatic cholesterol content in high-fat fed mice [99] and reduces
steatosis and liver injury in this stetting [242]. In addition to reducing
hepatic cholesterol statins have pleiotropic actions including anti-
inﬂammatory, immunomodulatory, antioxidative and antithrombotic
actions that may also be at play in the beneﬁcial effects observed in ex-
perimental NAFLD/NASH [241]. With regard to existing clinical data on
the effects of statin use on liver histology in NAFLD, studies are very
limited and conﬂicting [240,243,244]. The most recent study by
Dongiovanni et al. [245] clearly suggests a protective effect of statins
on liver histology in subjects with NASH. This retrospective but well
controlled and matched study demonstrated that statin use was associ-
ated with less intense histological liver damage. Interestingly, individ-
uals harboring the I148M PNPLA3 risk variant gained limited beneﬁt
from statin use. Clearly, randomized clinical trials of adequate size and
duration are needed to conﬁrm these ﬁndings. Of note, Dongiovanni
and other authors have reported that statins are under-prescribed in pa-
tients with NAFLD [240,245], since only 10% of adults with the disease
receive these drugs. This is indeed a low rate considering the cardiovas-
cular risk of this patient population and is likely related to a fear to liver
toxicity, which is a rather rare event [240]. Thus, dyslipidemia manage-
ment with statins should not be withheld in individuals with NAFLD as
this drug class signiﬁcantly reduces cardiovascular events in these pa-
tients [142] and might be of beneﬁt for liver disease.
With regard to ezetimibe, an agent that reduces intrahepatic choles-
terol by inhibiting cholesterol absorption from the intestine through in-
hibition of the NPC1L1 sterol transporter channel and modestly lowers
serum cholesterol levels [246], both preclinical studies [106,247] and
clinical data [248,249] suggest that ezetimibe may be beneﬁcial for
NAFLD. Interestingly, the combination of ezetimibe with statins, aiming
to enhance the hepatic effects of ezetimibe by inhibiting the compensa-
tory up-regulation of hepatic cholesterol synthesis induced by the de-
crease in hepatic cholesterol content, is markedly efﬁcient in reducing
hepatic FC content in experimental models having a signiﬁcant impact
in ongoing liver injury [99]. This data suggested that ezetimibe has po-
tential for NAFLD/NASH therapy. However, in a recent human trial
[250] showed that ezetimibe did not signiﬁcantly inﬂuence either liver
fat or liver histology in patients with NASH. Thus, further well-
designed randomized and fully powered trials are needed to establish
the role of ezetimibe in NAFLD.BA sequestrants (i.e., cholestyramine and colesevelam) are lipid-
lowering agents that decrease plasma and intrahepatic cholesterol
levels by promoting cholesterol catabolism through BA biosynthetic
pathways [251] and improving hepatic insulin sensitivity [252]. In addi-
tion, these agents exert a positive inﬂuence on glucose metabolism by
improving glycemic control in diabetic patients. Thus, BA sequestration
could be beneﬁcial for NAFLD treatment. However, current experimen-
tal and clinical data do not support this contention [253,254].
3.2. FXR agonists
Awealth of information regarding the critical role of FXR in a variety
of cellular processes in different tissues, mainly in the liver and intes-
tine, is available. One of themain FXR target genes is the short heterodi-
mer partner SHP, which controls the expression of CYP7A1, the key
enzyme in BA synthesis. Through this pathway, along with control of
BA import and export through the regulation of membrane trans-
porters, FXR regulates intracellular BA levels. This regulation is critical
for prevention of hepatocyte injury and death [255]. In addition, FXR in-
tricately controls different pathways in both lipid and carbohydrateme-
tabolism, which may be beneﬁcial in NAFLD [256,257]. A recent
controlled trial showed histological beneﬁts of a FXR agonist
(obeticholic acid) in patients with steatohepatitis [258]. The underlying
mechanisms of the positive effects of this drug in NASH likely occur at
multiple levels, including inhibition of de novo lipogenesis, stimulation
of lipolysis, reduction of the inﬂammatory response and stimulation of
intestinal pathways involving the secretion of FGF-19. Data on the ef-
fects of FXR agonists on hepatic cholesterol content is inconclusive
[259,260]; it should be kept in mind that FXR agonism may affect
serum lipoprotein concentrations through several mechanisms which
may determine cardiovascular risks. In addition other side effects such
as pruritus and a modest increase in insulin resistance were observed
in patients receiving obeticholic acid. These effects may impact the clin-
ical utility of this agent [261].
3.3. Other agents
Other potential approaches to unload cholesterol from the liver to
reduce hepatic injury in NAFLD/NASH include the use of thyromimetics
[56,262] and the activation of the glucagon-like peptide-1 receptor
(GLP-1R) that has been shown to reduce lipid accumulation in peripher-
al tissues and attenuate hepatic steatosis in preclinical studies [263,
264]. Other novel approaches could be targeting microRNAs that regu-
late hepatic cholesterol synthesis, such as the use of antisense-based si-
lencing of miR-122 [265], treatment with probiotics [266], which
indirectly inﬂuences cholesterol metabolism in the liver and modula-
tion of JNK1 activation that reduces ongoing liver cell death [186]. Fur-
ther studies are needed to clarify the potential of these approaches to
be exploited therapeutically.
4. Summary, conclusions and perspectives
In recent past, a growing body of evidence linking hepatic cholester-
ol accumulation to liver injury in setting of NAFLD/NASH had become
available. Dietary sources as well as an extensive derangement in
numerous steps of hepatic cholesterol homeostasis including activation
of cholesterol biosynthetic pathways, increased cholesterol de-
esteriﬁcation and attenuation of cholesterol export could contribute to
increase levels of FC both in hepatocytes and non-parenchymal hepatic
cells (i.e. KC and HSC) and thereby drive NAFLD/NASH disease progres-
sion. In hepatocytes, increased FC in subcellular compartments such as
the ER andmitochondria could trigger ER stress andmitochondrial dys-
function leading to cell death by necrosis and apoptosis. In addition, FC
promotes the activation of KC and HSC which fuels inﬂammation and
ﬁbrogenesis. Thus, hepatic accumulation of cholesterol rather than tri-
glycerides is associated to ongoing hepatocyte death and liver damage
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ple steatosis to steatohepatitis. Therefore, targeting cholesterol accumu-
lation represents a potentially useful therapeutic approach in NAFLD.
Unloading the liver from an excess of cholesterol in the clinical setting
would likely require a combination of dietary and pharmacological in-
terventions that need to be designed and validated. Currently used
drugs to treat hyperlipidemia may be of beneﬁt in NAFLD/NASH but
this speciﬁc effect warrants evaluation in large clinical trials. Also, new
approaches targeting nuclear receptors or cholesterol metabolism path-
ways may become useful to reduce hepatic FC content thus reducing
liver injury in NAFLD/NASH.
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